Technology

DongwhaPharm Appoints Cosmetics Expert Kim Ji-yoon as Head of the Health and Beauty Marketing Division

[Edaily Reporter NA EUN-KYUNG ] Donghwa Pharmaceutical ( DongwhaPharm(000020)) announced on the 29th that it has appointed Director Kim Ji-yoon as the new Head of the Lifestyle and Health Marketing Division. The Lifestyle and Health Marketing Division, which operates under the Lifestyle and Health Headquarters, oversees the Beauty Marketing Team and the Health Supplement Marketing Team.

Kim Ji-yoon, Head of the Lifestyle and Health Marketing Division at DongwhaPharm (Photo: DongwhaPharm)



Director Kim Ji-yoon is an expert who has led marketing efforts for various brands in the beauty industry. Starting in 2008 as the Head of the Color Cosmetics Business Management (BM) Division at LG H&H(051900), she went on to work at Celltrion Skin Cure and ABLE C&C(078520) ’s Misha, where she was responsible for brand marketing across various cosmetics categories, including color cosmetics and skincare.

In 2020, she joined CHONGKUNDANG Health as a director in the Cosmetics Business Division, leading the cosmetics business of the pharmaceutical affiliate. Director Kim will now oversee the brand strategy and marketing for DongwhaPharm’s beauty and health functional food brands.

A graduate of the Department of Business Administration at Chung-Ang University, Director Kim also contributed to the development of the Cosmetics Product Planning Strategy course at the Korea Health and Welfare Talent Institute in 2018.

Director Kim Ji-yoon stated, “Building on the brand marketing experience accumulated by DongwhaPharm over its 129-year history, I will work to create brands that are trusted and loved by consumers in the beauty and health functional food sectors.”

Economy

Corporation

IT·Science

Economy

A Semiconductor Fabless Company Founded by SK Hynix’s Youngest-Ever Executive [VC Cradle]

The biggest bottleneck for AI servers is memory. As the KV cache—where large language models (LLMs) store past computations—accumulates, the required memory capacity increases exponentially. This prob…
2026-07-04 09:00:07

Corporation

Genosco, Tax Risk?… “Lecraza Is ‘Royalty Income’; Its Value Remains Unchanged”

Concerns about “tax risks” have been raised in some quarters of the financial investment, pharmaceutical, and biotech markets regarding Genosco, a subsidiary of OSCOTEC Inc.(039200)specializing in new…
2026-07-04 08:31:02

IT·Science

Celltrion Pharm Inc. Builds a Plant, AriBio Secures Investment… K-Bio in ‘Expansion Mode’ [Weekly Bio Roundup]

As July began (June 29–July 3), the pharmaceutical and biotech industries turned their attention to Celltrion Pharm Inc.’s large-scale investment in production facilities and AriBio’s successful fundr…
2026-07-04 09:01:02